# Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

> **NCT03780010** · PHASE1 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 15 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** TRC105

## Key facts

- **NCT ID:** NCT03780010
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780010, "Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03780010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*